197 related articles for article (PubMed ID: 28923682)
1. Co-coating of receptor-targeted drug nanocarriers with anti-phagocytic moieties enhances specific tissue uptake versus non-specific phagocytic clearance.
Kim J; Sinha S; Solomon M; Perez-Herrero E; Hsu J; Tsinas Z; Muro S
Biomaterials; 2017 Dec; 147():14-25. PubMed ID: 28923682
[TBL] [Abstract][Full Text] [Related]
2. Effect of flow on endothelial endocytosis of nanocarriers targeted to ICAM-1.
Bhowmick T; Berk E; Cui X; Muzykantov VR; Muro S
J Control Release; 2012 Feb; 157(3):485-92. PubMed ID: 21951807
[TBL] [Abstract][Full Text] [Related]
3. Combination-targeting to multiple endothelial cell adhesion molecules modulates binding, endocytosis, and in vivo biodistribution of drug nanocarriers and their therapeutic cargoes.
Papademetriou I; Tsinas Z; Hsu J; Muro S
J Control Release; 2014 Aug; 188():87-98. PubMed ID: 24933603
[TBL] [Abstract][Full Text] [Related]
4. ICAM-1 targeting, intracellular trafficking, and functional activity of polymer nanocarriers coated with a fibrinogen-derived peptide for lysosomal enzyme replacement.
Garnacho C; Muro S
J Drug Target; 2017; 25(9-10):786-795. PubMed ID: 28665212
[TBL] [Abstract][Full Text] [Related]
5. PEGylated and CD47-conjugated nanoellipsoidal artificial antigen-presenting cells minimize phagocytosis and augment anti-tumor T-cell responses.
Song S; Jin X; Zhang L; Zhao C; Ding Y; Ang Q; Khaidav O; Shen C
Int J Nanomedicine; 2019; 14():2465-2483. PubMed ID: 31040669
[TBL] [Abstract][Full Text] [Related]
6. Specific binding, uptake, and transport of ICAM-1-targeted nanocarriers across endothelial and subendothelial cell components of the blood-brain barrier.
Hsu J; Rappaport J; Muro S
Pharm Res; 2014 Jul; 31(7):1855-66. PubMed ID: 24558007
[TBL] [Abstract][Full Text] [Related]
7. Endothelial targeting of high-affinity multivalent polymer nanocarriers directed to intercellular adhesion molecule 1.
Muro S; Dziubla T; Qiu W; Leferovich J; Cui X; Berk E; Muzykantov VR
J Pharmacol Exp Ther; 2006 Jun; 317(3):1161-9. PubMed ID: 16505161
[TBL] [Abstract][Full Text] [Related]
8. A fibrinogen-derived peptide provides intercellular adhesion molecule-1-specific targeting and intraendothelial transport of polymer nanocarriers in human cell cultures and mice.
Garnacho C; Serrano D; Muro S
J Pharmacol Exp Ther; 2012 Mar; 340(3):638-47. PubMed ID: 22160267
[TBL] [Abstract][Full Text] [Related]
9. Comparative binding, endocytosis, and biodistribution of antibodies and antibody-coated carriers for targeted delivery of lysosomal enzymes to ICAM-1 versus transferrin receptor.
Papademetriou J; Garnacho C; Serrano D; Bhowmick T; Schuchman EH; Muro S
J Inherit Metab Dis; 2013 May; 36(3):467-77. PubMed ID: 22968581
[TBL] [Abstract][Full Text] [Related]
10. Biodistribution and endocytosis of ICAM-1-targeting antibodies versus nanocarriers in the gastrointestinal tract in mice.
Mane V; Muro S
Int J Nanomedicine; 2012; 7():4223-37. PubMed ID: 22915850
[TBL] [Abstract][Full Text] [Related]
11. Delivery of acid sphingomyelinase in normal and niemann-pick disease mice using intercellular adhesion molecule-1-targeted polymer nanocarriers.
Garnacho C; Dhami R; Simone E; Dziubla T; Leferovich J; Schuchman EH; Muzykantov V; Muro S
J Pharmacol Exp Ther; 2008 May; 325(2):400-8. PubMed ID: 18287213
[TBL] [Abstract][Full Text] [Related]
12. In vivo performance of polymer nanocarriers dually-targeted to epitopes of the same or different receptors.
Papademetriou IT; Garnacho C; Schuchman EH; Muro S
Biomaterials; 2013 Apr; 34(13):3459-66. PubMed ID: 23398883
[TBL] [Abstract][Full Text] [Related]
13. Targeting, endocytosis, and lysosomal delivery of active enzymes to model human neurons by ICAM-1-targeted nanocarriers.
Hsu J; Hoenicka J; Muro S
Pharm Res; 2015 Apr; 32(4):1264-78. PubMed ID: 25319100
[TBL] [Abstract][Full Text] [Related]
14. Biological functionalization of drug delivery carriers to bypass size restrictions of receptor-mediated endocytosis independently from receptor targeting.
Ansar M; Serrano D; Papademetriou I; Bhowmick TK; Muro S
ACS Nano; 2013 Dec; 7(12):10597-611. PubMed ID: 24237309
[TBL] [Abstract][Full Text] [Related]
15. PLGA nanoparticle--peptide conjugate effectively targets intercellular cell-adhesion molecule-1.
Zhang N; Chittasupho C; Duangrat C; Siahaan TJ; Berkland C
Bioconjug Chem; 2008 Jan; 19(1):145-52. PubMed ID: 17997512
[TBL] [Abstract][Full Text] [Related]
16. RhoA activation and actin reorganization involved in endothelial CAM-mediated endocytosis of anti-PECAM carriers: critical role for tyrosine 686 in the cytoplasmic tail of PECAM-1.
Garnacho C; Shuvaev V; Thomas A; McKenna L; Sun J; Koval M; Albelda S; Muzykantov V; Muro S
Blood; 2008 Mar; 111(6):3024-33. PubMed ID: 18182571
[TBL] [Abstract][Full Text] [Related]
17. Enhanced endothelial delivery and biochemical effects of α-galactosidase by ICAM-1-targeted nanocarriers for Fabry disease.
Hsu J; Serrano D; Bhowmick T; Kumar K; Shen Y; Kuo YC; Garnacho C; Muro S
J Control Release; 2011 Feb; 149(3):323-31. PubMed ID: 21047542
[TBL] [Abstract][Full Text] [Related]
18. ICAM-1 recycling in endothelial cells: a novel pathway for sustained intracellular delivery and prolonged effects of drugs.
Muro S; Gajewski C; Koval M; Muzykantov VR
Blood; 2005 Jan; 105(2):650-8. PubMed ID: 15367437
[TBL] [Abstract][Full Text] [Related]
19. Enhanced Delivery and Effects of Acid Sphingomyelinase by ICAM-1-Targeted Nanocarriers in Type B Niemann-Pick Disease Mice.
Garnacho C; Dhami R; Solomon M; Schuchman EH; Muro S
Mol Ther; 2017 Jul; 25(7):1686-1696. PubMed ID: 28606376
[TBL] [Abstract][Full Text] [Related]
20. Effect of acid sphingomyelinase deficiency in type A Niemann-Pick disease on the transport of therapeutic nanocarriers across the blood-brain barrier.
Loeck M; Placci M; Muro S
Drug Deliv Transl Res; 2023 Dec; 13(12):3077-3093. PubMed ID: 37341882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
